Fragment-based exploration of the 14-3-3/Amot-p130 interface

Adams, 2010, PHENIX: a comprehensive Python-based system for macromolecular structure solution, Acta Crystallogr. Sect. D Biol. Crystallogr., 66, 213, 10.1107/S0907444909052925 Adler, 2013, Serum deprivation inhibits the transcriptional Co-activator YAP and cell growth via phosphorylation of the 130-KDa isoform of Angiomotin by the LATS1/2 protein kinases, Proc. Natl. Acad. Sci. U. S. A, 110, 17368, 10.1073/pnas.1308236110 Adler, 2013, Amot130 adapts Atrophin-1 interacting protein 4 to inhibit yes-associated protein signaling and cell growth, J. Biol. Chem., 288, 15181, 10.1074/jbc.M112.446534 Anders, 2013, A semisynthetic fusicoccane stabilizes a protein-protein interaction and enhances the expression of K+ channels at the cell surface, Chem. Biol., 20, 583, 10.1016/j.chembiol.2013.03.015 Andrei, 2017, Stabilization of protein-protein interactions in drug discovery, Expet Opin. Drug Discov., 12, 925, 10.1080/17460441.2017.1346608 Andrei, 2018, Rationally designed semisynthetic natural product analogues for stabilization of 14 -3-3Protein –ProteinInteractions, Angew. Chem. Int. Ed., 57, 13470, 10.1002/anie.201806584 Arkin, 2004, Small-molecule inhibitors of protein–protein interactions: progressing towards the dream, Nat. Rev. Drug Discov., 3, 301, 10.1038/nrd1343 Ballone, 2018, 14-3-3: a case study in PPI modulation, Molecules, 23, 1386, 10.3390/molecules23061386 Ballone, 2018, Structural characterization of 14-3-3ζ in complex with the human Son of Sevenless Homolog 1 (SOS1), J. Struct. Biol., 202, 210, 10.1016/j.jsb.2018.01.011 Bartel, 2014, Small molecules, peptides and natural products: getting a grip on 14-3-3 protein-protein modulation, Future Med. Chem., 6, 903, 10.4155/fmc.14.47 Bier, 2016, Small-molecule stabilization of the 14-3-3/Gab2 protein–protein interaction (PPI) interface, ChemMedChem, 11, 911, 10.1002/cmdc.201500484 Bissantz, 2010, Medicinal chemist's guide to molecular interactions, J. Med. Chem., 53, 5061, 10.1021/jm100112j Bratt, 2002, Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains, Gene, 298, 69, 10.1016/S0378-1119(02)00928-9 Bratt, 2005, Angiomotin regulates endothelial cell-cell junctions and cell motility, J. Biol. Chem., 280, 34859, 10.1074/jbc.M503915200 Brown, 2018, Approaches to target tractability assessment – a practical perspective, Med. Chem. Commun., 9, 606, 10.1039/C7MD00633K Centorrino, 2018, Biophysical and structural insight into the USP8/14-3-3 interaction, FEBS Lett., 592, 1211, 10.1002/1873-3468.13017 DeLano, 2002, Pymol: an open-source molecular graphics tool, 40, 82 Emsley, 2004, Coot: model-building tools for molecular graphics, Acta Crystallogr. Sect. D Biol. Crystallogr., 60, 2126, 10.1107/S0907444904019158 Ernkvist, 2006, P130-Angiomotin associates to actin and controls endothelial cell shape, FEBS J., 273, 2000, 10.1111/j.1742-4658.2006.05216.x Gogl, 2021, Hierarchized phosphotarget binding by the seven human 14-3-3 isoforms, Nat. Commun., 12, 1677, 10.1038/s41467-021-21908-8 Guillory, 2020, Fragment-based differential targeting of PPI stabilizer interfaces, J. Med. Chem., 63, 6694, 10.1021/acs.jmedchem.9b01942 Huang, 2018, The physiological role of Motin family and its dysregulation in tumorigenesis, J. Transl. Med., 16, 98, 10.1186/s12967-018-1466-y Hughes, 2017, Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders, Essays Biochem., 61, 505, 10.1042/EBC20170041 Humphrey, 1996, VMD: visual molecular dynamics, J. Mol. Graph., 14, 33, 10.1016/0263-7855(96)00018-5 Johnson, 2010, Bioinformatic and experimental survey of 14-3-3-binding sites, Biochem. J., 427, 69, 10.1042/BJ20091834 Kanai, 2000, TAZ: a novel transcriptional Co-activator regulated by interactions with 14-3-3 and PDZ domain proteins, EMBO J., 19, 6778, 10.1093/emboj/19.24.6778 Kilisch, 2016, Dual phosphorylation switch controls 14-3-3-dependent cell surface expression of TASK-1, J. Cell Sci., 129, 831 Leach, 2011, Molecular complexity and fragment-based drug discovery: ten years on, Curr. Opin. Chem. Biol., 15, 489, 10.1016/j.cbpa.2011.05.008 Lentini Santo, 2020, Stabilization of protein-protein interactions between CaMKK2 and 14-3-3 by fusicoccins, ACS Chem. Biol., 15, 3060, 10.1021/acschembio.0c00821 Leysen, 2021, Structural insights into the cytoplasmic chaperone effect of 14-3-3 proteins on Ataxin-1, J. Mol. Biol., 433, 10.1016/j.jmb.2021.167174 Lv, 2017, Angiomotin family members: oncogenes or tumor suppressors?, Int. J. Biol. Sci., 13, 772, 10.7150/ijbs.19603 Mabonga, 2019, Protein-protein interaction modulators: advances, successes and remaining challenges, Biophys. Rev., 11, 559, 10.1007/s12551-019-00570-x McCoy, 2007, Phaser crystallographic software, J. Appl. Crystallogr., 40, 658, 10.1107/S0021889807021206 Milroy, 2014, Modulators of protein–protein interactions, Chem. Rev., 114, 4695, 10.1021/cr400698c Moleirinho, 2017, Regulation of localization and function of the transcriptional Co-activator YAP by Angiomotin, Elife, 6, 10.7554/eLife.23966 Platzer, 2020, PI by NMR: probing CH–π interactions in protein–ligand complexes by NMR spectroscopy, Angew. Chem. Int. Ed., 59, 14861, 10.1002/anie.202003732 Rainard, 2018, Using microscale Thermophoresis to characterize hits from high-throughput screening: a European lead factory perspective, SLAS Discov., 23, 225, 10.1177/2472555217744728 Salonen, 2011, Aromatic rings in chemical and biological recognition: energetics and structures, Angew. Chem. Int. Ed., 50, 4808, 10.1002/anie.201007560 Schreiber, 2021, The rise of molecular glues, Cell, 184, 3, 10.1016/j.cell.2020.12.020 Scott, 2016, Small molecules, big targets: drug discovery faces the protein–protein interaction challenge, Nat. Rev. Drug Discov., 15, 533, 10.1038/nrd.2016.29 Souers, 2013, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat. Med., 19, 202, 10.1038/nm.3048 Stevers, 2016, Characterization and small-molecule stabilization of the multisite Tandem binding between 14-3-3 and the R domain of CFTR, Proc. Natl. Acad. Sci. U. S. A, 113, E1152, 10.1073/pnas.1516631113 Troyanovsky, 2001, Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation, J. Cell Biol., 152, 1247, 10.1083/jcb.152.6.1247 Valenti, 2019, Clinical candidates modulating protein-protein interactions: the fragment-based experience, Eur. J. Med. Chem., 167, 76, 10.1016/j.ejmech.2019.01.084 Vidal, 2011, Interactome networks and human disease, Cell, 144, 986, 10.1016/j.cell.2011.02.016 Webb, 2011, Structural features and ligand binding properties of Tandem WW domains from YAP and TAZ, nuclear effectors of the Hippo pathway, Biochemistry, 50, 3300, 10.1021/bi2001888 Winter, 2018, DIALS: implementation and evaluation of a new integration package, Acta Crystallogr. D Struct. Biol., 74, 85, 10.1107/S2059798317017235 Wolter, 2020, Selectivity via cooperativity: preferential stabilization of the P65/14-3-3 interaction with semisynthetic natural products, J. Am. Chem. Soc., 142, 11772, 10.1021/jacs.0c02151 Würtele, 2003, Structural view of a fungal toxin acting on a 14-3-3 regulatory complex, EMBO J., 22, 987, 10.1093/emboj/cdg104 Yu, 2015, Hippo pathway in organ size control, tissue homeostasis, and cancer, Cell, 163, 811, 10.1016/j.cell.2015.10.044 Zhao, 2007, Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control, Genes Dev., 21, 2747, 10.1101/gad.1602907 Zhao, 2011, Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein, Genes Dev., 25, 51, 10.1101/gad.2000111